Summary
Background: Data mining is a technique for discovering useful information hidden in a database, which has recently been used by the chemical, financial, pharmaceutical, and insurance industries. It may enable us to detect the interesting and hidden data on useful drugs especially in the field of cardiovascular disease.
Methods: & Results: We evaluated the current treatments for chronic heart failure (CHF) in our institute using a decision tree method of data mining and compared the results with those of large-scale clinical trials. We enrolled 1,100 patients with CHF (NYHA classes II–IV and EF < 40%) who were hospitalized at the National Cardiovascular Center during the past 31 months. Drugs prescribed at discharge were extracted from the clinical database. Both echocardiograms and plasma BNP level at 6–12 months after discharge were determined prospectively. It was found that beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin II receptor antagonists independently improve both the plasma BNP level and %fractional shortening (FS), while oral inotropic agents increased the plasma BNP level and decreased %FS. These findings agree with evidence accumulated from several large-scale trials. Interestingly, statins, histamine receptor blockers, and alpha-glucosidase inhibitors also attenuated the severity of CHF, suggesting the possibility of new treatment of CHF.
Conclusion: Clinical data mining using Japanese CHF patients yielded almost identical data to the results of large-scale trials, and also suggested novel and unexpected candidates for CHF therapy. Further validation of the data mining approved in the cardiovascular field is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The ALLHAT Officers Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007.
Doggrell SA ACE inhibitors versus diuretics: ALLHAT versus ANBP2. Expert Opin Pharmacother 2003;4:825–828.
Podgorelec V, Kokol P, Stiglic B, et al. Decision trees: An overview and their use in medicine. Med Syst. 2002;26(5):445–463.
Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807–2816.
Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970–975.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.
Nicod P, Gilpin E, Dittrich H, Chappuis F, et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol 1988;61:1165– 1171.
Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392–2397.
Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278–1283.
Hina K, Kusachi S, Iwasaki K, et al. Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: Incidence and prognostic value. Clin Cardiol 1993;16:403–407.
Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429–1437.
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108(7):839–843.
Kahraman A, Erkasap N, Ken T, et al. The antioxidative and antihistaminic properties of quercetin in ethanol-induced gastric lesions. Toxicology 2003;183:133–142.
Dyess DL, Hunter JL, Lakey JR, et al. Attenuation of histamine-induced endothelial permeability responses after pacing-induced heart failure: Role for endogenous catecholamines. Microcirculation 2000;7:307–315.
Hara M, Matsumori A, Ono K, et al. Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 1999;100:1443–1449.
Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003;107:1486–1491.
Stumpf C, Lehner C, Yilmaz A, et al. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci 2003;105(1):45–50.
Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: A brief review. Cardiovasc Toxicol 2001;1:181–193.
Singal PK, Bell Klein A, Farahmand F, et al. Oxidative stress and functional deficit in diabetic cardiomyopathy. Adv Exp Med Biol 2001;498:213–220.
Li Y, Huang TT, Carlson EJ, Melov S, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995;11:376–381.
Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211–214.
Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;19;363(9426):2010–2011.
Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomized controlled trial. Lancet 2004.) Early online publication.
Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004;18(1):57–66.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, J., Washio, T., Yamagishi, M. et al. A Novel Data Mining Approach to the Identification of Effective Drugs or Combinations for Targeted Endpoints—Application to Chronic Heart Failure as a New Form of Evidence-based Medicine. Cardiovasc Drugs Ther 18, 483–489 (2004). https://doi.org/10.1007/s10557-004-6226-y
Issue Date:
DOI: https://doi.org/10.1007/s10557-004-6226-y